Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hypogonadism Trial Designs: FDA Panel Favors Symptom Assessments, Fertility Measures

Executive Summary

US advisory committee rejects Repros Therapeutics' proposal for an obesity-related hypogonadism study in which efficacy is based upon testosterone levels and sperm concentrations.


Related Content

US FDA's New Hypogonadism Guidance Focuses On Non-Testosterone Products
CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End
Real World Evidence: ‘Hot Topic’ At US FDA, But Not On Front Burner
Recent And Upcoming FDA Advisory Committees
FDA’s Tough Stance On Patient-Reported Outcomes Underscored At Repros Meeting
FDA/Industry Dispute On Hypogonadism Drug Efficacy Endpoints To Get Panel Review
Repros Therapeutics Needs New Pivotal Trial For Low T Drug Enclomiphene


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts